ROS1 and glioblastoma: Entrectinib, a first-generation ROS1 TKI, has CNS activity and second generation ROS1 TKIs in clinical development such as repotrectinib, taletrectinib and NVL-520, also has either demonstrated CNS activity clinically or in pre-clinical models and thus could be considered as a potential treatment option for ROS1+ GBM patients [9, 11–13].